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tions of Scalzo and collegues (Scalzo et al., 1990) initiallyHe Who Laughs Last Laughs Best—
led to the genetic dissection of CMV resistance in mice.Innate Immunity and Viral Selection The resistant allele is Ly49h on chromosome 6 (Lee et
al., 2001; Brown et al., 2001; Daniel et al., 2001), and it
encodes a membrane receptor capable of binding to a
viral product, m157. m157 is an MHC class I-like protein
In this issue of Immunity, the Jonjic and Yokoyama expressed at the surface of infected cells (Arase et al.,
teams provide evidence that -herpesvirus mutants 2002; Smith et al., 2002). The m157-Ly49H interaction
can emerge under the selective pressure of innate triggers the cytolytic machinery of NK cells and the pro-
immunity during primary infections. These rare mu- duction of interferon-. Thus, Ly49H NK cells are
tants that escape natural killer cell recognition cause thought to protect mice by killing infected cells and by
disease and death in mice that lack sterilizing T cell im- the antimicrobial and proinflammatory action of inter-
munity. feron-.
In this issue of Immunity, the Jonjic and Yokoyama
The complex interactions between genomes of large teams put a new emphasis on the importance of m157-
DNA viruses and host immune systems are the result Ly49H interactions during primary infection (French et
of millions of years of coevolution. Cytomegalovirus al., 2004). The authors set out to study CMV-infected
(CMV), a member of the herpesvirus family, has an im- SCID mice in order to gain insight into the fate of the
pressive array of genes that can neutralize, evade, and pathogen and the role of innate immunity in the presence
exploit even the most robust immune response (Mocar- of adaptive immunodeficiency. SCID mice lack T cells,
ski, 2002; Alcami, 2003). However, a delicate balance but because of Ly49H NK cells they had highly effective
between the two partners develops, and so infections innate immune responses and could control early viral
of healthy adults usually cause no major disease. The replication just as well as immunocompetent mice. As
virus evades clearance by the immune system, persists expected, the NK response did not completely clear the
for a lifetime, and keeps infecting new hosts to spread virus, and in the absence of a subsequent adaptive (T
further. But as it takes two to tango; when the host cell-mediated) response, MCMV replicated uncontrolla-
immune system fails to respond adequately to the virus, bly, causing morbidity and mortality in the immunodefi-
the lonely partner loses the sense of balance and causes cient SCID mice. The surprising finding was that the
life-threatening damage. Thus, primary infection or reac- vast majority of isolates from the spleens of surviving
tivation of latent CMV can cause severe disease and SCID mice harbored viruses that no longer expressed
death in very young children and immunocompromised a wild-type m157 protein.
individuals such as AIDS or organ transplant patients Repeated passages of MCMCV in Ly49H resistant
(Britt and Alford, 1996). mice were previously shown to create enough selective
Natural killer cells are believed to be the bouncers of pressure for the virus to change its hat and lose the
the immune system and might have evolved under the expression of m157, limiting NK cell recognition (Voigt
pressure of pathogens (Parham, 2003). When they are et al., 2003). The important new finding by French et al.
absent, viral replication is often poorly controlled. Thus, is that such immunoselection can occur during primary
a child with faulty NK cell functions developed recurrent infection. The mutant viruses replicate extensively dur-
and eventually lethal herpesvirus infections (Biron et al., ing subsequent infections, even in Ly49H immunocom-
1989). Analysis of CMV infections of mice has greatly petent mice, because of the absence of m157 recogni-
contributed to our understanding of the immunology of tion by NK cells.
the infection, establishing NK cells as the main cellular How general a mechanism is escape of NK recognition
by m157 mutation? Although Ly49H NK cells do makeactors of the early response to the virus. The observa-
Previews
657
a difference between susceptibility and resistance in tory receptors on NK cells (Cohen et al., 1999). Indeed,
laboratory mice, the immune response to the virus is HCMV can even encourage the expression of HLA-E,
organized by complex networks of cells, soluble factors, thus enhancing NK cell inhibition (Tomasec et al., 2000).
cellular receptors, and intracellular signaling pathways, Specific inhibition of immune responses may be ex-
all of which are potential targets for the viral escapolo- tended to other leukocytes. Carbone and colleagues
gist. Therefore, tunes other than that based on the have elegantly shown a positive correlation between
Ly49H-m157 interaction are played during the long-last- LIR-1 lymphocytes and CMV-induced morbility/mortal-
ing dance between the virus and the host immune sys- ity in lung transplant patients (Berg et al., 2003). LIR-1
tem (Mocarski, 2002; Alcami, 2003). (leucocyte immunoglobulin-like receptor-1, also called
First, the m157-encoded protein is recognized by dif- ILT-2, CD85j) is an inhibitory cell surface receptor on
ferent Ly49 receptors in mouse strains that lack Ly49H various lymphoid and myeloid cells that has high affinity
(Arase et al., 2002; Smith et al., 2002). For example, the for an MHC class I homolog (UL18) encoded by human
inhibitory Ly49I receptor of 129/J mice binds to it and cytomegalovirus (Cosman et al., 1999).
129/J mice are susceptible to MCVM. In addition, m157 Recent data suggest that human NK receptors may
is one of at least eleven MCMV ORFs with the potential function in a manner similar to LY49H in CMV-resistant
to code MHC class I folds. NK cell-mediated and Ly49H- mice. Killer immunoglobulin-like (KIR) receptors are the
independent mechanisms of resistance to CMV are functional homologs of rodent Ly49 receptors. HIV pa-
present in wild-derived mice (S.M.V., Guenet, and F.C., tients coexpressing the activating KIR3DS1 and HLA-B
unpublished data). How these interactions contribute to have delayed progression to AIDS (Martin et al., 2002).
MCMV resistance or susceptibility in vivo has yet to be Thus, in clinical settings innate immune receptors seem
clarified, and other Ly49 genes might participate in these actively engaged by the virus. It would be interesting to
interactions. However, it is expected that MHC class analyze genomic sequences of clinical HCMV isolates to
I-like genes will be under diverse selective pressures in seek for clustering of mutations at specific virus genes.
different hosts. These pressures can eventually produce UL18, or other MHC class I like genes, would be attrac-
escape mutants in some mouse strains but not in others. tive candidates to study. Of course, it would be impor-
Second, Ly49H mice can be made susceptible to tant to carry such studies with due consideration of
CMV. Cytokines and chemokines are crucial players variations in host genetics, as studies in mice have
(Biron et al., 1999; Alcami, 2003), and defective signaling taught us that viral responses differ according to host
downstream of TLR3 and TLR9 leads to reduced pro- genetic backgrounds.
duction of type I interferon, resulting in high viral titers Identification of viral genes interacting with innate im-
in spite of the expression of Ly49H by NK cells (Tabeta mune responses may provide targets for developing
et al., 2004). therapies against infection. It would be paradoxical for
Third, a common theme of viral strategy in human as the virus that the clinical immunologist might exploit its
well as rodent hosts consists in blocking the expression sophisticated escape strategy to combat against the
of inducible cellular genes that are recognized by the virus itself. The work by French et al. may lead this way.
activating receptor NKG2D. These MHC-like products
are signals of cellular stress that mark infected and tu-
mor cells as targets for NK cells. Krmpotic et al. have Francesco Colucci1 and Silvia M. Vidal2
recently shown that Ly49H-negative BALB/c mice sus- 1Department of Immunology
ceptible to wild-type CMV are in fact resistant to mutant Pasteur Institute
CMV lacking the m152 gene responsible for this evasion 25-28 rue Dr Roux
strategy (Krmpotic et al., 2002). Importantly, UL16 of 75015 Paris
human CMV interferes with the expression of MIC-B, France
ULBP1, and ULBP2, which are the ligands for human 2 Department of Human Genetics
NKG2D (Dunn et al., 2003). The net result is prevention McGill University
of killing through NKG2D signaling in both species, al- 3445 University Street
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unique to each pathogen. So, Ly49H-m157 is not the Canada
answer to all questions. It would be interesting to deter-
mine if the innate response of mouse strains with various Selected Reading
genetic make-ups might select escape mutants with
Alcami, A. (2003). Nat. Rev. Immunol. 3, 36–50.mutations at genes other than m157.
What is the significance of these new rodent data in Arase, H., Mocarski, E.S., Campbell, A.E., Hill, A.B., and Lanier, L.L.
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